Jm. Cooney et al., SPECIFICITY OF THE PYRIDOSTIGMINE GROWTH-HORMONE CHALLENGE IN THE DIAGNOSIS OF DEPRESSION, Biological psychiatry, 42(9), 1997, pp. 827-833
Acetylcholine is a neurotransmitter that has been implicated in the pa
thophysiology of major depression, This is supported by the enhanced g
rowth hormone (GH) release in response to pyridostigmine (PYD) challen
ge in depressed subjects relative to healthy comparison subjects. The
nim of this study is to examine the specificity of the PYD/GH challeng
e in the diagnosis of depression, Pyridostigmine 120 mg orally, was ad
ministered to a total of 116 physically healthy subjects. Growth hormo
ne responses were studied in 38 patients with (DSM-III-R) major depres
sion, 13 subjects with panic disorder, 9 subjects with schizophrenia,
10 recently detoxified alcoholics, and a comparison group of 45 health
y volunteers. Mean Delta CH (the difference between basal and maximal
GH following PYD) was significantly, greater than comparison subjects
in patients with major depression. Responses observed in patients with
schizophrenia and alcohol dependence syndrome did not differ from the
comparison group, Those patients with panic disorder and a high Hamil
ton depression score had an enhanced Delta GH. The sensitivity of the
PYD/GH rest was 63% for major depression. These results indicate that
the PYD/GH test may help distinguish depression from schizophrenia, al
cohol-dependence syndrome, or panic disorder with a low Hamilton depre
ssion score. (C) 1997 Society of Biological Psychiatry.